Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia

Leukemia

Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review

Leuk Lymphoma

Korsholm C, Bülow C, Christensen M, Dalhoff K, Feinberg JB, Lund TM, Niemann CU, Petersen TS, Andersen MA

doi: 10.1080/10428194.2024.2412289

Multiple Myeloma (MM)

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Blood Cancer J

Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, Kubicki T, Jakubowiak AJ

doi: 10.1038/s41408-024-01156-x

Leukemia

Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia

Leukemia

Orvain C, Milano F, Rodríguez-Arbolí E, Othus M, Petersdorf EW, Sandmaier BM, Appelbaum FR, Walter RB

doi: 10.1038/s41375-024-02497-z

Leukemia

Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Leuk Lymphoma

Shadman M, Salkar M, Srivastava B, Karve S, Emond B, Gogna P, Manceur AM, Lafeuille MH, Rava A, Sun H, Howarth A, Tomicki S, Agatep B, Jones B, Franceschini E, Saifan C, Bacchus S, Roeker L, Stephens DM

doi: 10.1080/10428194.2024.2402814

Leukemia

Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA

J Clin Oncol

Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Šimkovič M, Österborg A, Laurenti L, Walker PA, Opat SS, Ciepluch H, Greil R, Hanna M, Tani M, Trněný M, Brander D, Flinn IW, Grosicki S, Verner E, Tedeschi A, de Guibert S, Tumyan G, Laribi K, García-Marco JA, Li JY, Tian T, Liu Y, Korolkiewicz R, Szeto A, Tam CS, Jurczak W

doi: 10.1200/JCO-24-02265

Leukemia

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

Blood

Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh MM, Mishra A, Muffly L, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson KJ, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal AM, Devine SM, Horowitz MM, Chen YB

doi: 10.1182/blood.2024025154

Leukemia

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

J Clin Oncol

Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, Mátrai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM

doi: 10.1200/JCO-25-00166

Leukemia

Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation

Br J Haematol

Perutelli F, Boccellato E, Montalbano MC, Catania G, Deodato M, Frustaci AM, Innocenti I, Moia R, Quaglia FM, Quaresmini G, Rivela P, Gaidano G, Krampera M, Laurenti L, Rambaldi A, Bruno B, Vitale C, Coscia M

doi: 10.1111/bjh.19976

Leukemia

Ibrutinib Lead-in followed by Venetoclax Plus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia - SAKK 34/17

Blood

Condoluci A, Romano I, Dietrich D, Pini K, Stussi G, Müller G, Cantoni N, Cathomas R, Mey UJM, Widmer AA, Zenz T, Gregor M, Heim D, Andres M, Benz R, Rossi D

doi: 10.1182/blood.2024026879

Related content

Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia

Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation

Ibrutinib Lead-in followed by Venetoclax Plus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia - SAKK 34/17